Neprilysin

Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT.

Also Known As:

Neutral Endopeptidase; Atriopeptidase; CD10 Antigen; Enkephalinase-24.11; Neutral Endopeptidase 24.11; Thermolysin-Like Metalloendopeptidase; YGG-Forming Enzyme; Antigen, CD10; Carboxypeptidase, Enkephalin Dipeptidyl; Dipeptidyl Carboxypeptidase, Enkephalin; Endopeptidase 24.11; Endopeptidase 24.11, Neutral; Endopeptidase, Neutral; Enkephalinase 24.11; Enzyme, YGG-Forming; Kidney Brush Border Neutral Proteinase; Membrane Metallo Endopeptidase; Metallo-Endopeptidase, Membrane; Metalloendopeptidase, Thermolysin-Like; Neutral Proteinase, Kidney-Brush-Border; Thermolysin Like Metalloendopeptidase; YGG Forming Enzyme; Antigens, CD10; Antigens, Leukemia, Common Acute Lymphoblastic; CALLA Antigen; CD10 Antigens; Common Acute Lymphoblastic Leukemia Antigens; Endopeptidase-24.11; Enkephalin Dipeptidyl Carboxypeptidase; Enkephalinase; Kidney-Brush-Border Neutral Proteinase; Membrane Metallo-Endopeptidase

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Hydrolases: 2166
    - Peptide Hydrolases: 23957
      - Metalloproteases: 8276
        Metalloendopeptidases: 70
        Neprilysin: 1845
      - Endopeptidases: 633
        Metalloendopeptidases: 70
        Neprilysin: 1845
Biological Factors: 2472
- Biomarkers: 240291
  - Tumor Biomarkers: 15272
    - Neprilysin: 1845
- Antigens: 143924
  - Neoplasm Antigens: 6217
    - Neprilysin: 1845

Anya Spungin Selected Research

Anya Spungin Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure